α-Tocotrienol-quinone, a vitamin E metabolite, has had some success in small open label trials in reversing early onset vision loss [REF].
There are various treatment approaches which have had early trials or are proposed, none yet with convincing evidence of usefulness or safety for treatment or prevention including brimonidine,[REF] minocycline,[REF] curcumin,[REF] glutathione,[REF] near infrared light treatment,[REF] and viral vector techniques [REF].